U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Triple-Negative Breast Cancer Finding

MedGen UID:
418132
•Concept ID:
C2348819
•
Finding
Synonyms: ER-Negative PR-Negative ERBB2-Negative; ER/PR/HER2 Negative; ESR1/PGR/ERBB2 Negative Finding; Triple Negative Breast Cancer Finding; Triple Negative Breast Cancer Result; Triple-Negative Breast Cancer Result

Definition

Triple-negative breast cancer finding is a negative test result that occurs when the cells in the tumor of a breast cancer patient lack the receptors for both estrogen and progesterone and the human epidermal growth factor receptor 2. [from NCI]

Professional guidelines

PubMed

Treatment of Breast Cancer in Young Adults.
Tesch ME, Partridge AH
Am Soc Clin Oncol Educ Book 2022 Apr;42:1-12. doi: 10.1200/EDBK_360970. PMID: 35580291
Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.
Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, Xiao Y, Yu KD, Liu YR, Yu Y, Zheng Y, Li X, Zhang C, Hu P, Zhang J, Hua Q, Zhang J, Hou W, Ren L, Bao D, Li B, Yang J, Yao L, Zuo WJ, Zhao S, Gong Y, Ren YX, Zhao YX, Yang YS, Niu Z, Cao ZG, Stover DG, Verschraegen C, Kaklamani V, Daemen A, Benson JR, Takabe K, Bai F, Li DQ, Wang P, Shi L, Huang W, Shao ZM
Cancer Cell 2019 Mar 18;35(3):428-440.e5. Epub 2019 Mar 7 doi: 10.1016/j.ccell.2019.02.001. PMID: 30853353
Breast Cancer Treatment: A Review.
Waks AG, Winer EP
JAMA 2019 Jan 22;321(3):288-300. doi: 10.1001/jama.2018.19323. PMID: 30667505

Recent clinical studies

Etiology

Triple-Negative Breast Cancer: Histopathologic Features, Genomics, and Treatment.
Adrada BE, Moseley TW, Kapoor MM, Scoggins ME, Patel MM, Perez F, Nia ES, Khazai L, Arribas E, Rauch GM, Guirguis MS
Radiographics 2023 Oct;43(10):e230034. doi: 10.1148/rg.230034. PMID: 37792593Free PMC Article
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment.
Garrido-Castro AC, Lin NU, Polyak K
Cancer Discov 2019 Feb;9(2):176-198. Epub 2019 Jan 24 doi: 10.1158/2159-8290.CD-18-1177. PMID: 30679171Free PMC Article
Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.
Baretta Z, Mocellin S, Goldin E, Olopade OI, Huo D
Medicine (Baltimore) 2016 Oct;95(40):e4975. doi: 10.1097/MD.0000000000004975. PMID: 27749552Free PMC Article
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA
PLoS One 2016;11(6):e0157368. Epub 2016 Jun 16 doi: 10.1371/journal.pone.0157368. PMID: 27310713Free PMC Article
An overview of triple-negative breast cancer.
Kumar P, Aggarwal R
Arch Gynecol Obstet 2016 Feb;293(2):247-69. Epub 2015 Sep 4 doi: 10.1007/s00404-015-3859-y. PMID: 26341644

Diagnosis

Advances in systemic therapies for triple negative breast cancer.
Leon-Ferre RA, Goetz MP
BMJ 2023 May 30;381:e071674. doi: 10.1136/bmj-2022-071674. PMID: 37253507
Recent advances in therapeutic strategies for triple-negative breast cancer.
Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, Chen Y
J Hematol Oncol 2022 Aug 29;15(1):121. doi: 10.1186/s13045-022-01341-0. PMID: 36038913Free PMC Article
Triple-negative breast cancer: promising prognostic biomarkers currently in development.
Sukumar J, Gast K, Quiroga D, Lustberg M, Williams N
Expert Rev Anticancer Ther 2021 Feb;21(2):135-148. doi: 10.1080/14737140.2021.1840984. PMID: 33198517Free PMC Article
Pathology of triple negative breast cancer.
Borri F, Granaglia A
Semin Cancer Biol 2021 Jul;72:136-145. Epub 2020 Jun 13 doi: 10.1016/j.semcancer.2020.06.005. PMID: 32544511
Role of Immunotherapy in Triple-Negative Breast Cancer.
Keenan TE, Tolaney SM
J Natl Compr Canc Netw 2020 Apr;18(4):479-489. doi: 10.6004/jnccn.2020.7554. PMID: 32259782

Therapy

Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery.
Zou Y, Xie J, Zheng S, Liu W, Tang Y, Tian W, Deng X, Wu L, Zhang Y, Wong CW, Tan D, Liu Q, Xie X
Int J Surg 2022 Nov;107:106936. Epub 2022 Sep 20 doi: 10.1016/j.ijsu.2022.106936. PMID: 36341760
Metabolic reprogramming in triple-negative breast cancer.
Wang Z, Jiang Q, Dong C
Cancer Biol Med 2020 Feb 15;17(1):44-59. doi: 10.20892/j.issn.2095-3941.2019.0210. PMID: 32296576Free PMC Article
Role of Immunotherapy in Triple-Negative Breast Cancer.
Keenan TE, Tolaney SM
J Natl Compr Canc Netw 2020 Apr;18(4):479-489. doi: 10.6004/jnccn.2020.7554. PMID: 32259782
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Trial Investigators
N Engl J Med 2018 Nov 29;379(22):2108-2121. Epub 2018 Oct 20 doi: 10.1056/NEJMoa1809615. PMID: 30345906
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L
Nat Rev Clin Oncol 2016 Nov;13(11):674-690. Epub 2016 May 17 doi: 10.1038/nrclinonc.2016.66. PMID: 27184417Free PMC Article

Prognosis

Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery.
Zou Y, Xie J, Zheng S, Liu W, Tang Y, Tian W, Deng X, Wu L, Zhang Y, Wong CW, Tan D, Liu Q, Xie X
Int J Surg 2022 Nov;107:106936. Epub 2022 Sep 20 doi: 10.1016/j.ijsu.2022.106936. PMID: 36341760
Recent advances in therapeutic strategies for triple-negative breast cancer.
Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, Chen Y
J Hematol Oncol 2022 Aug 29;15(1):121. doi: 10.1186/s13045-022-01341-0. PMID: 36038913Free PMC Article
Triple-negative breast cancer: promising prognostic biomarkers currently in development.
Sukumar J, Gast K, Quiroga D, Lustberg M, Williams N
Expert Rev Anticancer Ther 2021 Feb;21(2):135-148. doi: 10.1080/14737140.2021.1840984. PMID: 33198517Free PMC Article
Pathology of triple negative breast cancer.
Borri F, Granaglia A
Semin Cancer Biol 2021 Jul;72:136-145. Epub 2020 Jun 13 doi: 10.1016/j.semcancer.2020.06.005. PMID: 32544511
An overview of triple-negative breast cancer.
Kumar P, Aggarwal R
Arch Gynecol Obstet 2016 Feb;293(2):247-69. Epub 2015 Sep 4 doi: 10.1007/s00404-015-3859-y. PMID: 26341644

Clinical prediction guides

Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery.
Zou Y, Xie J, Zheng S, Liu W, Tang Y, Tian W, Deng X, Wu L, Zhang Y, Wong CW, Tan D, Liu Q, Xie X
Int J Surg 2022 Nov;107:106936. Epub 2022 Sep 20 doi: 10.1016/j.ijsu.2022.106936. PMID: 36341760
Triple-negative breast cancer: promising prognostic biomarkers currently in development.
Sukumar J, Gast K, Quiroga D, Lustberg M, Williams N
Expert Rev Anticancer Ther 2021 Feb;21(2):135-148. doi: 10.1080/14737140.2021.1840984. PMID: 33198517Free PMC Article
Pathology of triple negative breast cancer.
Borri F, Granaglia A
Semin Cancer Biol 2021 Jul;72:136-145. Epub 2020 Jun 13 doi: 10.1016/j.semcancer.2020.06.005. PMID: 32544511
Genetic Markers in Triple-Negative Breast Cancer.
Sporikova Z, Koudelakova V, Trojanec R, Hajduch M
Clin Breast Cancer 2018 Oct;18(5):e841-e850. Epub 2018 Aug 4 doi: 10.1016/j.clbc.2018.07.023. PMID: 30146351
An overview of triple-negative breast cancer.
Kumar P, Aggarwal R
Arch Gynecol Obstet 2016 Feb;293(2):247-69. Epub 2015 Sep 4 doi: 10.1007/s00404-015-3859-y. PMID: 26341644

Recent systematic reviews

Platinum-based chemotherapy for early triple-negative breast cancer.
Mason SR, Willson ML, Egger SJ, Beith J, Dear RF, Goodwin A
Cochrane Database Syst Rev 2023 Sep 8;9(9):CD014805. doi: 10.1002/14651858.CD014805.pub2. PMID: 37681577Free PMC Article
Signaling Pathways and Natural Compounds in Triple-Negative Breast Cancer Cell Line.
Dewi C, Fristiohady A, Amalia R, Khairul Ikram NK, Ibrahim S, Muchtaridi M
Molecules 2022 Jun 7;27(12) doi: 10.3390/molecules27123661. PMID: 35744786Free PMC Article
Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis.
Conforti F, Pala L, Sala I, Oriecuia C, De Pas T, Specchia C, Graffeo R, Pagan E, Queirolo P, Pennacchioli E, Colleoni M, Viale G, Bagnardi V, Gelber RD
BMJ 2021 Dec 21;375:e066381. doi: 10.1136/bmj-2021-066381. PMID: 34933868Free PMC Article
Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
Poggio F, Bruzzone M, Ceppi M, Pondé NF, La Valle G, Del Mastro L, de Azambuja E, Lambertini M
Ann Oncol 2018 Jul 1;29(7):1497-1508. doi: 10.1093/annonc/mdy127. PMID: 29873695
Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.
Baretta Z, Mocellin S, Goldin E, Olopade OI, Huo D
Medicine (Baltimore) 2016 Oct;95(40):e4975. doi: 10.1097/MD.0000000000004975. PMID: 27749552Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • ClinVar
      Related medical variations
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...